ArticleClinical kidney journal2025
Association of pancreas fat fraction with adverse kidney and cardiovascular outcomes.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of Lifestyle Modification on Intrapancreatic Fat Deposition: A Systematic Review and Meta-Analysis.Current obesity reports · 2026Pooled it
- Fatty Pancreas and Risk of Type 2 Diabetes, Chronic Kidney Disease and Cardiovascular Events: Evidence From a Population-Based Cohort.United European gastroenterology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background: Pancreas fat accumulation has been associated with impaired glucose metabolism and stimulation of inflammation. The associations of pancreatic fat fraction (PFF) with adverse outcomes remain understudied. Methods: We estimated baseline predicted PFF (pPFF) from abdominal magnetic resonance imaging (MRI) in 29 447 UK Biobank participants. Since the initial imaging visit occurred 9.3 [interquartile range (IQR) 8.2-10.2] years after baseline visit, we calculated annual change in PFF using linear regression in 337 participants who underwent repeat imaging 2.8 (IQR 2.2-4.8) years after the initial scan. We back-calculated pPFF by adding this change to each participant based on the time between baseline visit and initial MRI visit assuming linear change in PFF over time. Multivariable-adjusted proportional hazards models tested associations of pPFF with incident chronic kidney disease (CKD), cardiovascular disease (CVD) and death. Results: Participants had a mean ± standard deviation age of 56 ± 8 years, mean eGFR of 98 ± 13 mL/min/1.73 m Conclusions: Higher pPFF levels are associated with higher risk of incident CKD and CVD but not death. Future studies should investigate whether pancreas fat depots should serve as a target of current or emerging therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.